Invest in InDex
Pharmaceuticals

InDex Pharmaceuticals Holding AB (publ) published its interim report Q2 for January-June 2021 on August 25, 2021 at 08:00 a.m. CEST.

InDex Pharmaceuticals in numbers

  • 15-30

    The most common age of an ulcerative colitis diagnosis

  • 2 Million

    Patients living with ulcerative colitis in the US and Europe

  • 6.3 billion USD

    Total yearly sales of medications for ulcerative colitis

  • 8 billion USD

    The estimated total yearly sales of medication for ulcerative colitis in 2023

InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis.

Investor contact

Peter Zerhouni
Peter Zerhouni
+46 8 122 038 50